Who are urate oxidase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan medoxomil+probenecid, Pegloticase with MTX, Rasburicase (SR29142), SEL-212 high-dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/urate-oxidase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

urate oxidase — Competitive Intelligence Brief

urate oxidase (urate oxidase) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Uricosuric enzyme. Area: Oncology; Rheumatology.

marketed Uricosuric enzyme Uric acid Oncology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

urate oxidase (urate oxidase) — Sanofi. Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
urate oxidase TARGET	urate oxidase	Sanofi	marketed	Uricosuric enzyme	Uric acid
olmesartan medoxomil+probenecid	olmesartan medoxomil+probenecid	Central South University	marketed	Angiotensin II receptor blocker + uricosuric agent	AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)
Pegloticase with MTX	Pegloticase with MTX	Amgen	marketed	Recombinant uricase (pegylated enzyme)	Uric acid (substrate); reduces anti-pegloticase antibodies via MTX immunosuppression
Rasburicase (SR29142)	Rasburicase (SR29142)	Sanofi	marketed	Recombinant urate oxidase	Uric acid (substrate); urate oxidase enzyme
SEL-212 high-dose	SEL-212 high-dose	Swedish Orphan Biovitrum	phase 3	Uricase with immunosuppressant combination	Uric acid (via pegsiticase uricase enzyme)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Uricosuric enzyme class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). urate oxidase — Competitive Intelligence Brief. https://druglandscape.com/ci/urate-oxidase. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab